Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE BrokerBank Securities, Inc.
NEW YORK, July 14, 2014 /PRNewswire/ -- Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biopharmaceutical competitor is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box®. This unique technology is intended for use as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built.
Researchers have estimated that the value of the pancreatic cancer market in the US and 5EU (France, Germany, Italy, Spain, and the UK) in 2012 was $529m. This market is defined as sales of branded drugs and major generic regimens commonly prescribed for pancreatic cancer patients across the six major markets (6MM). Just over half of these sales, $275m (52%), were generated in the US, while sales in the 5EU were estimated at $254m (48%).
The recent announcement of a new financing arrangement combined with the anticipated commencement of additional clinical trials could provide news and fundamental catalysts in the current speculative environment for the sector and the Company.
An analyst report which details key attributes of the technology, an overview of the company, recent developments and an analyst potentials and risks summary can be viewed in its entirety by using the link below. There is no cost obligation required to view this report:
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Michael Anderegg, Chartered Financial Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the full analyst report.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at email@example.com. For any urgent concerns or inquiries please contact us at firstname.lastname@example.org.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
©2012 PR Newswire. All Rights Reserved.